Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (10242)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Nov 6, 2016 (publication date) through Apr 24, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastrointestinal Pharmacology and Therapeutics
ISSN
2150-5349
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Yamada S, Kawakami T, Nakatsugawa Y, Suzuki T, Fujii H, Tomatsuri N, Nakamura H, Sato H, Okuyama Y, Kimura H, Yoshida N. Usefulness of vonoprazan, a potassium ion-competitive acid blocker, for primary eradication of Helicobacter pylori. World J Gastrointest Pharmacol Ther 2016; 7(4): 550-555 [PMID: 27867688 DOI: 10.4292/wjgpt.v7.i4.550] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v7/i4/550.htm |
| Number | Citing Articles |
| 1 |
Ligang Liu, Milap C. Nahata. Vonoprazan With Amoxicillin or Amoxicillin and Clarithromycin for the Treatment of Helicobacter pylori Infection. Annals of Pharmacotherapy 2023; 57(10): 1185 doi: 10.1177/10600280221149708
|
| 2 |
Anthony O'Connor, Dominique Lamarque, Javier P. Gisbert, Colm O'Morain. Treatment of Helicobacter pylori infection 2017. Helicobacter 2017; 22(S1) doi: 10.1111/hel.12410
|
| 3 |
Juan Wang, Yue Yue Li, Min Juan Lin, Jing Liu, Bo Shen Lin, Yu Ming Ding, Meng Wan, Wen Lin Zhang, Qing Zhou Kong, Shao Tong Wang, Yi Jun Mu, Miao Duan, Zhong Xue Han, Xiu Li Zuo, Yan Qing Li. Vonoprazan is noninferior to proton pump inhibitors in bismuth‐containing quadruple therapy for the treatment of Helicobacter pylori infection: A propensity score matching analysis. Journal of Digestive Diseases 2023; 24(1): 19 doi: 10.1111/1751-2980.13166
|
| 4 |
Irene Martinucci, Corrado Blandizzi, Giorgia Bodini, Elisa Marabotto, Vincenzo Savarino, Santino Marchi, Nicola de Bortoli, Edoardo Savarino. Vonoprazan fumarate for the management of acid-related diseases. Expert Opinion on Pharmacotherapy 2017; 18(11): 1145 doi: 10.1080/14656566.2017.1346087
|
| 5 |
Shu Kiyotoki, Jun Nishikawa, Isao Sakaida. Efficacy of Vonoprazan for <i>Helicobacter pylori</i> Eradication. Internal Medicine 2020; 59(2): 153 doi: 10.2169/internalmedicine.2521-18
|
| 6 |
Carmelo Scarpignato, Colin W. Howden, Eckhard Leifke, Darcy J. Mulford, Gezim Lahu, Axel Facius, Richard Hunt. A translational pharmacokinetic/pharmacodynamic approach supports optimal vonoprazan dosing for erosive oesophagitis and Helicobacter pylori infection. Alimentary Pharmacology & Therapeutics 2023; 58(1): 16 doi: 10.1111/apt.17510
|
| 7 |
Amin Talebi Bezmin Abadi, Enzo Ierardi. Vonoprazan and Helicobacter pylori Treatment: A Lesson From Japan or a Limited Geographic Phenomenon?. Frontiers in Pharmacology 2019; 10 doi: 10.3389/fphar.2019.00316
|
| 8 |
Mitsushige Sugimoto, Daiki Hira, Masaki Murata, Takashi Kawai, Tomohiro Terada. Effect of Antibiotic Susceptibility and CYP3A4/5 and CYP2C19 Genotype on the Outcome of Vonoprazan-Containing Helicobacter pylori Eradication Therapy. Antibiotics 2020; 9(10): 645 doi: 10.3390/antibiotics9100645
|
| 9 |
Yoshimasa Saito, Kaho Konno, Moeka Sato, Masaru Nakano, Yukako Kato, Hidetsugu Saito, Hiroshi Serizawa. Vonoprazan-Based Third-Line Therapy Has a Higher Eradication Rate against Sitafloxacin-Resistant Helicobacter pylori. Cancers 2019; 11(1): 116 doi: 10.3390/cancers11010116
|
| 10 |
Shou Quan Dong, Tikka Prabhjot Singh, Xin Wei, Huang Yao, Hong Ling Wang. Review: A Japanese population‐based meta‐analysis of vonoprazan versus PPI for Helicobacter pylori eradication therapy: Is superiority an illusion?. Helicobacter 2017; 22(6) doi: 10.1111/hel.12438
|
| 11 |
Soichiro Sue, Shin Maeda. Is a Potassium-Competitive Acid Blocker Truly Superior to Proton Pump Inhibitors in Terms of Helicobacter pylori Eradication?. Gut and Liver 2021; 15(6): 799 doi: 10.5009/gnl20242
|
| 12 |
Kazumi Inokuchi, Hideki Mori, Juntaro Matsuzaki, Kenro Hirata, Yosuke Harada, Yoshimasa Saito, Hidekazu Suzuki, Takanori Kanai, Tatsuhiro Masaoka. Efficacy and safety of low‐dose rifabutin‐based 7‐day triple therapy as a third‐ or later‐lineHelicobacter pylorieradication regimen. Helicobacter 2022; 27(4) doi: 10.1111/hel.12900
|
| 13 |
Xiaoxiao Yang, Yueyue Li, Yiyuan Sun, Mingming Zhang, Chuanguo Guo, Iqtida Ahmed Mirza, Yan-Qing Li. Vonoprazan: A Novel and Potent Alternative in the Treatment of Acid-Related Diseases. Digestive Diseases and Sciences 2018; 63(2): 302 doi: 10.1007/s10620-017-4866-6
|
| 14 |
Muhammad Miftahussurur, Boby Pratama Putra, Yoshio Yamaoka. The Potential Benefits of Vonoprazan as Helicobacter pylori Infection Therapy. Pharmaceuticals 2020; 13(10): 276 doi: 10.3390/ph13100276
|
| 15 |
慧 杨. Meta-Analysis of Vonoprazan for Helicobacter pylori Remedy Eradication Therapy. Advances in Clinical Medicine 2023; 13(12): 20498 doi: 10.12677/ACM.2023.13122883
|
| 16 |
Mariko Hojo, Daisuke Asaoka, Tsutomu Takeda, Yuji Shimada, Kenshi Matsumoto, Kohei Matsumoto, Noboru Yatagai, Yoichi Akazawa, Kumiko Ueda, Hiroya Ueyama, Akihito Nagahara. Randomized controlled study on the effects of triple therapy including vonoprazan or rabeprazole for the second-line treatment of Helicobacter pylori infection. Therapeutic Advances in Gastroenterology 2020; 13: 175628482096624 doi: 10.1177/1756284820966247
|
| 17 |
Maho Kusunoki, Mika Yuki, Hitomi Ishitobi, Yoshiya Kobayashi, Makoto Nagaoka, Yoshiko Takahashi, Nobuhiko Fukuba, Yoshinori Komazawa, Toshihiro Shizuku, Yoshikazu Kinoshita. Effect of Age on Effectiveness of Vonoprazan in Triple Therapy for <i>Helicobacter pylori</i> Eradication. Internal Medicine 2019; 58(11): 1549 doi: 10.2169/internalmedicine.2233-18
|
| 18 |
Amin Talebi Bezmin Abadi, Yoshio Yamaoka. Helicobacter pylori therapy and clinical perspective. Journal of Global Antimicrobial Resistance 2018; 14: 111 doi: 10.1016/j.jgar.2018.03.005
|
| 19 |
Y. S. Jung, E. H. Kim, C. H. Park. Systematic review with meta‐analysis: the efficacy of vonoprazan‐based triple therapy on Helicobacter pylori eradication. Alimentary Pharmacology & Therapeutics 2017; 46(2): 106 doi: 10.1111/apt.14130
|
| 20 |
Mika Miura, Masahiko Ohtaka, Mitsuhiko Hanawa, Naoki Shimura, Yoshioki Yoda, Sho Suzuki. Gastric Mucosal Atrophy Might Be Associated with the Efficacy of First-Line Therapy Using Vonoprazan for <i>Helicobacter pylori</i>. Open Journal of Gastroenterology 2017; 7(09): 243 doi: 10.4236/ojgas.2017.79026
|
| 21 |
Jong Kyu Park. Role of Potassium-Competitive Acid Blockers inHelicobacter pyloriEradication. The Korean Journal of Helicobacter and Upper Gastrointestinal Research 2017; 17(1): 20 doi: 10.7704/kjhugr.2017.17.1.20
|
| 22 |
Haruhiko Ozaki, Satoshi Harada, Toshihisa Takeuchi, Shinpei Kawaguchi, Yoshiaki Takahashi, Yuichi Kojima, Kazuhiro Ota, Yasushi Hongo, Kiyoshi Ashida, Masahiro Sakaguchi, Satoshi Tokioka, Hiroki Sakamoto, Takahisa Furuta, Kazunari Tominaga, Kazuhide Higuchi. Vonoprazan, a Novel Potassium-Competitive Acid Blocker, Should Be Used for the Helicobacter pylori Eradication Therapy as First Choice: A Large Sample Study of Vonoprazan in Real World Compared with Our Randomized Control Trial Using Second-Generation Proton Pump Inhibitors for Helicobacter pylori Eradication Therapy. Digestion 2018; 97(3): 212 doi: 10.1159/000485097
|
| 23 |
Wentao Xu, Zhaohui Bai, Yiyang Shang, Jing Wang, Yujun Wong, Xingshun Qi. Incidence and type of adverse events in patients taking vonoprazan: A systematic review and meta-analysis. Therapeutic Advances in Gastroenterology 2023; 16: 175628482311678 doi: 10.1177/17562848231167858
|
| 24 |
Mitsushige Sugimoto, Yoshio Yamaoka. Role of Vonoprazan in Helicobacter pylori Eradication Therapy in Japan. Frontiers in Pharmacology 2019; 9 doi: 10.3389/fphar.2018.01560
|